SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership changes first announced in January 2026.

The Board has appointed Ross Muken, currently President, as Chief Executive Officer, effective July 1, 2026, and nominated him for election as a member of the Board of Directors. Furthermore, as set out in the AGM Invitation published on May 8, 2026, the Board of Directors has nominated Dr. Jurgi Camblong, co-founder and current Chief Executive Officer, for election as Chairman of the Board of Directors. Troy Cox, who has served as Chairman since March 2020, has been nominated for re-election as a non-executive member of the Board.